ENTRY       D06272                      Drug
NAME        Sorafenib tosylate (USAN);
            Sorafenib tosilate (JAN);
            Nexavar (TN)
PRODUCT     NEXAVAR (Bayer HealthCare Pharmaceuticals)
  GENERIC   SORAFENIB (Dr.Reddys Laboratories)
            SORAFENIB (Golden State Medical Supply)
            SORAFENIB (TWi Pharmaceuticals USA)
            SORAFENIB (Teva Pharmaceuticals)
            SORAFENIB (Torrent Pharmaceuticals Limited)
            SORAFENIB (Yabao Pharmaceutical)
            SORAFENIB TOSYLATE (Mylan Pharmaceuticals)
FORMULA     C21H16ClF3N4O3. C7H8O3S
EXACT_MASS  636.1057
MOL_WEIGHT  637.0266
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01EX02
            Chemical structure group: DG00713
            Product (DG00713): D06272<JP/US>
EFFICACY    Antineoplastic, Tyrosine kinase inhibitor
  DISEASE   Hepatocellular carcinoma [DS:H00048]
            Renal cell carcinoma [DS:H00021]
            Thyroid carcinoma [DS:H00032]
TARGET      RAF1 [HSA:5894] [KO:K04366]
            BRAF [HSA:673] [KO:K04365]
            FLT3 (CD135) [HSA:2322] [KO:K05092]
            PDGFRB [HSA:5159] [KO:K05089]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            VEGFR3 (FLT4) [HSA:2324] [KO:K05097]
            KIT (CD117) [HSA:3815] [KO:K05091]
            RET [HSA:5979] [KO:K05126]
  PATHWAY   hsa04010(2322+2324+3791+3815+5159+5894+673)  MAPK signaling pathway
            hsa04012(5894+673)  ErbB signaling pathway
            hsa04370(3791+5894)  VEGF signaling pathway
            hsa05200(2322+2324+3815+5159+5894+5979+673)  Pathways in cancer
            hsa05211(5894+673)  Renal cell carcinoma
            hsa05216(5979+673)  Thyroid cancer
            hsa05225(5894+673)  Hepatocellular carcinoma
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EX Other protein kinase inhibitors
                 L01EX02 Sorafenib
                  D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Sorafenib
                D06272  Sorafenib tosylate (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D06272  Sorafenib tosylate (USAN); Sorafenib tosilate (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG00713  Sorafenib
                D06272  Sorafenib tosylate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Serine/threonine kinases
               TKL group
                BRAF
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
                RAF1
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
              Receptor tyrosine kinases (RTK)
               PDGFR family
                PDGFRB
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
                KIT (CD117)
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
                FLT3 (CD135)
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
               VEGFR family
                VEGFR2 (KDR)
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
                VEGFR3 (FLT4)
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
               RET family
                RET
                 D06272  Sorafenib tosylate (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06272
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D06272
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D06272
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06272
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG00713  Sorafenib
DBLINKS     CAS: 475207-59-1
            PubChem: 47207930
            LigandBox: D06272
ATOM        43
            1   C8y C    41.3134  -16.2561
            2   C8x C    40.1203  -16.9579
            3   C8x C    42.5767  -16.9579
            4   S4a S    41.3134  -14.8525
            5   C8x C    40.1203  -18.3616
            6   C8x C    42.5767  -18.3616
            7   O1d O    39.9098  -14.8525
            8   O1d O    42.7170  -14.8525
            9   O1d O    41.3134  -13.5191
            10  C8y C    41.3134  -19.0634
            11  C1a C    41.2961  -20.4669
            12  C8x C    34.7102  -17.2381
            13  C8y C    34.7102  -18.6418
            14  C8x C    35.9257  -19.3436
            15  C8x C    37.1414  -18.6418
            16  C8y C    37.1414  -17.2381
            17  C8y C    35.9257  -16.5363
            18  X   Cl   38.3757  -16.5253
            19  C1d C    35.9257  -15.1329
            20  X   F    35.9383  -13.7295
            21  N1b N    33.4946  -19.3436
            22  C5a C    32.2961  -18.6514
            23  N1b N    31.1056  -19.3387
            24  O5a O    32.2960  -17.2384
            25  C8y C    29.9113  -18.6489
            26  C8x C    29.9113  -17.2383
            27  C8x C    28.6958  -16.5365
            28  C8y C    27.4802  -17.2383
            29  C8x C    27.4801  -18.6488
            30  C8x C    28.6957  -19.3507
            31  O2a O    26.2656  -16.5369
            32  C8y C    25.0675  -17.2288
            33  C8x C    23.8769  -16.5413
            34  C8y C    22.6613  -17.2431
            35  N5x N    22.6613  -18.6468
            36  C8x C    23.8519  -19.3342
            37  C8x C    25.0675  -18.6324
            38  C5a C    21.4269  -16.5303
            39  N1b N    20.2231  -17.2254
            40  O5a O    21.4271  -15.1328
            41  C1a C    19.0354  -16.5396
            42  X   F    34.5100  -15.1267
            43  X   F    37.3099  -15.1389
BOND        45
            1     1   2 1
            2     1   3 2
            3     1   4 1
            4     2   5 2
            5     3   6 1
            6     4   7 2
            7     4   8 2
            8     4   9 1
            9     5  10 1
            10    6  10 2
            11   10  11 1
            12   12  13 2
            13   13  14 1
            14   14  15 2
            15   15  16 1
            16   16  17 2
            17   12  17 1
            18   16  18 1
            19   17  19 1
            20   19  20 1
            21   13  21 1
            22   21  22 1
            23   22  23 1
            24   22  24 2
            25   23  25 1
            26   25  26 2
            27   26  27 1
            28   27  28 2
            29   28  29 1
            30   29  30 2
            31   25  30 1
            32   28  31 1
            33   31  32 1
            34   32  33 2
            35   33  34 1
            36   34  35 2
            37   35  36 1
            38   36  37 2
            39   32  37 1
            40   34  38 1
            41   38  39 1
            42   38  40 2
            43   39  41 1
            44   19  42 1
            45   19  43 1
///
